Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …

Real-time quantitative PCR (qPCR) is routinely used to detect minimal residual disease in
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …

Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an
important clinical test for the management of patients with chronic myeloid leukemia …

BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …

Quantitative real-time PCR methods are commonly used to monitor BCR-ABL transcript
levels in patients with chronic myelogenous leukemia. However, standard techniques …

Measurement of BCR activator of RhoGEF and GTPase‐ABL proto‐oncogene 1, non‐
receptor tyrosine kinase (BCR‐ABL1) mRNA levels by reverse transcription quantitative …

BACKGROUND Current guidelines for managing Philadelphia-positive chronic myeloid
leukemia include monitoring the expression of the BCR-ABL1 (breakpoint cluster region/c …

Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …

Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …